Diadema Partners’s Contineum Therapeutics CTNM Stock Holding History

Diadema Partners’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96M	Buy	+119,733	New	+$1.57M	0.25%	78

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Diadema Partners's CTNM Position: Q2 2026 in Review

Diadema Partners opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 119,733 shares worth $1.96M. The stake represents 0.25% of the portfolio and ranks #78 among its holdings.

102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Diadema Partners held 119,733 shares of Contineum Therapeutics worth $1.96M as of Q2 2026.
Contineum Therapeutics was a new Diadema Partners position in Q2 2026.
Contineum Therapeutics made up 0.25% of Diadema Partners's portfolio in Q2 2026, its #78 holding.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.